Human leukocyte antigen (HLA) compatibility has no clinically significant impact in cadaveric liver transplantation. Less is known regarding living-donor liver transplantation (LDLT). Our prior analysis of the Organ Procurement and Transplantation Network (OPTN) database suggested a higher graft fai
Long-term outcome of human leukocyte antigen mismatching in liver transplantation: Results of the national institute of diabetes and digestive and kidney diseases liver transplantation database
โ Scribed by Vijayan Balan; Kris Ruppert; A. Jake Demetris; Tatiana Ledneva; Rene J. Duquesnoy; Katherine M. Detre; Yuling L. Wei; Jorge Rakela; Daniel F. Schafer; John P. Roberts; James E. Everhart; Russell H. Wiesner
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 662 KB
- Volume
- 48
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
โฆ Synopsis
A perfect or nearly perfect human leukocyte antigen (HLA) match has been associated with better immediate and long-term survival of diseased donor kidney transplants. However, the effect of HLA matching for hepatic allografts remains poorly defined. Using data from the National Institutes of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database, we investigated the association between HLA mismatches and hepatic allograft survival, disease recurrence, and immunosuppression interactions. A, B, and DR loci were used to calculate total mismatch scores of 0 (no mismatches in any loci) to 6 (mismatches in all loci). Seven hundred ninety-nine adults (male, 55%; female, 45%) underwent 883 liver transplants. The 10-year graft survival according to total mismatch score was as follows: 0-2, 60%; 3-4, 54%; and 5-6, 57%. There was a negative effect of mismatching at the A locus on patient survival, with shorter survival for patients with 1 or 2 mismatches compared with 0 mismatches [P โซุโฌ 0.05, hazard ratio (HR) โซุโฌ 1.6]. Patients on tacrolimus with 1 or 2 mismatches at B or DR loci appeared to have increased rates of patient and graft survival compared to patients with 0 mismatches, with the appearance of a protective effect of tacrolimus (HR โซุโฌ 0.67). The effect of HLA mismatching was more pronounced on certain disease recurrences. DR-locus mismatch increased recurrence of autoimmune hepatitis (P โซุโฌ 0.01, HR โซุโฌ 4.2) and primary biliary cirrhosis (P โซุโฌ 0.04, HR โซุโฌ 2). Mismatch in the A locus was associated with more recurrence of hepatitis C virus (P โซุโฌ 0.01, HR โซุโฌ 1.6) and primary sclerosing cholangitis (P โซุโฌ 0.03, HR โซุโฌ 2.9). Conclusion: Mismatching at the A locus decreases patient survival in liver transplant recipients, and mismatching at the DR and A loci affects recurrence of autoimmune liver diseases and hepatitis C, respectively.
๐ SIMILAR VOLUMES
## Hepatitis C virus (HCV)-associated liver disease is the most common indication for liver transplantation (LT). There are, however, no long-term (>5 year) studies of comparative outcomes for recipients with HCV infection, and no models capable of identifying recipients with HCV infection at great